BioSpace News Archive

Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, provided an update on its product pipeline and the timeline to results for the company’s three ongoing clinical trials, including the Phase 3 trial of OTIVIDEX in Ménière’s disease.

ChemoCentryx, Inc. announced the completion of its follow-on offering of 5,200,000 shares of its common stock.

CareDx, Inc., a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the closing of its previously announced public offering of 3,906,250 shares of its common stock at a public offering price of $32.00 per share.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Laurent Fischer, M.D. has joined the company as its chief executive officer and a member of the board of directors.

Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in fireside chats at two upcoming virtual investor conferences.

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock.

Today, the U.S. Food and Drug Administration (FDA) permitted marketing of the first game-based digital therapeutic device to improve attention function in children with attention deficit hyperactivity disorder (ADHD)

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT (5:00 p.m. ET) on Monday, June 22, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.

AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Stephen R. Master, MD, PhD, FAACC, has been elected to serve on the AACC Board of Directors as president-elect starting in August 2020.